TNBC accounts for approximately 15–20% of all breast cancer cases and is more aggressive than other types of breast cancer due to the absence of these receptors, making it less responsive to hormone therapy, chemotherapy, or HER2-targeted therapies [2]. This evidence concerns the gene ERBB2 and breast carcinoma.